The Office of Research & Development, Periyar Maniammai Institute of Science & Technology (Deemed to be University), Thanjavur 613 403, Tamil Nadu, India; School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor, Malaysia.
Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Al-Qara, Abha 61421, Saudi Arabia.
Cell Signal. 2024 Dec;124:111461. doi: 10.1016/j.cellsig.2024.111461. Epub 2024 Oct 9.
Perivascular adipose tissue (PVAT) is found locally around blood vessels. It has the ability to release vasoactive chemicals, such as factors that relax and contract blood vessels. PVAT is now recognized as an endocrine organ with metabolic activity and as a "protagonist" for maintaining vascular homeostasis. Angiotensin II, a powerful vasoconstrictor of the renin-angiotensin system (RAS) that can increase blood pressure and vascular tone, is produced locally by PVAT. To mitigate the multiple vascular effects of angiotensin II, PVAT also generates molecules such as angiotensin (1-7), adiponectin, and nitric oxide. Reactive oxygen species and proinflammatory cytokines are produced in greater amounts when PVAT-mediated angiotensin II is present, resulting in endothelial dysfunction, inflammation, atherosclerosis, and other vascular disorders. The anticontractile and procontractile nature of PVAT is frequently disrupted in obese individuals, which increases the production of angiotensin II and decreases the production of anti-inflammatory and vasodilatory factors. These changes in turn exacerbate vascular inflammation, hypertension, and atherosclerosis. PVAT, which is crucial for maintaining vascular homeostasis, loses its anticontractile effect in obesity due to adipocyte hypertrophy, inflammation, and oxidative stress, exacerbating endothelial dysfunction. Overactive RAS in PVAT facilitates the migration and proliferation of vascular smooth muscle cells and atherosclerotic plaques, both of which accelerate the development of atherosclerosis. Targeting PVAT and the local RAS can offer therapeutic benefits in treating hypertension, atherosclerosis, and other vascular diseases. This review highlights the scientific underpinnings of the function of PVAT in regulating the autocrine and paracrine activities of vascular RAS constituents.
血管周脂肪组织(PVAT)位于血管周围局部。它具有释放血管活性化学物质的能力,例如能使血管舒张和收缩的因子。现在,PVAT 被认为是具有代谢活性的内分泌器官,也是维持血管内环境稳定的“主角”。血管紧张素 II 是肾素-血管紧张素系统(RAS)的一种强大的血管收缩剂,可升高血压和血管张力,由 PVAT 局部产生。为了减轻血管紧张素 II 的多种血管作用,PVAT 还产生血管紧张素(1-7)、脂联素和一氧化氮等分子。当存在由 PVAT 介导的血管紧张素 II 时,会产生更多的活性氧和促炎细胞因子,导致内皮功能障碍、炎症、动脉粥样硬化和其他血管疾病。肥胖个体中 PVAT 的抗收缩和促收缩性质经常受到干扰,这会增加血管紧张素 II 的产生并减少抗炎和血管舒张因子的产生。这些变化反过来又会加剧血管炎症、高血压和动脉粥样硬化。PVAT 对维持血管内环境稳定至关重要,但由于脂肪细胞肥大、炎症和氧化应激,其抗收缩作用在肥胖中丧失,从而加剧内皮功能障碍。PVAT 中过度活跃的 RAS 促进血管平滑肌细胞和动脉粥样硬化斑块的迁移和增殖,这两者都加速了动脉粥样硬化的发展。针对 PVAT 和局部 RAS 可以在治疗高血压、动脉粥样硬化和其他血管疾病方面带来治疗益处。本综述强调了 PVAT 在调节血管 RAS 成分的自分泌和旁分泌活性中的功能的科学基础。